Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pemetrexed safety and dosing strategy.

Clet Niyikiza1, Axel-R Hanauske, James J Rusthoven

  • 1Eli Lilly and Company, Indianapolis, IN 46285, USA.

Seminars in Oncology
|February 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine Learning Assessment of Pathologic Response in Lung Cancer Resections After Neoadjuvant Therapy-IASLC MPR Project.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.

Clinical lung cancer·2026
Same author

The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.

Ecancermedicalscience·2026
Same author

Wide complex tachycardia in the emergency department: an updated approach to diagnosis and management.

Emergency medicine practice·2026
Same author

Corrigendum to 'Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact' [Journal of Thoracic Oncology Volume 21 Issue 1 (2026) 41-76].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Pemetrexed toxicity can be predicted by vitamin deficiency markers like homocysteine. Supplementing with folic acid and vitamin B12 improves pemetrexed safety without reducing its effectiveness.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Pemetrexed is an antifolate chemotherapy agent targeting key enzymes in folate metabolism.
  • Antifolates, including pemetrexed, can cause severe myelosuppression and gastrointestinal toxicity.
  • These toxicities, especially in combination, pose a significant risk of life-threatening complications.

Purpose of the Study:

  • To evaluate the predictability of severe pemetrexed toxicity using vitamin deficiency markers.
  • To assess the impact of folic acid and vitamin B12 supplementation on pemetrexed safety and efficacy.

Main Methods:

  • Utilized homocysteine and methylmalonic acid as markers for vitamin deficiency.
  • Investigated the effect of reducing plasma homocysteine levels through vitamin supplementation.

Related Experiment Videos

  • Assessed changes in toxicity profiles and therapeutic efficacy.

    • Main Results:

    • Severe pemetrexed toxicity is predictable using homocysteine and methylmalonic acid levels.
    • Supplementation with folic acid and vitamin B12 effectively reduces total plasma homocysteine.
    • Vitamin supplementation improved the safety profile of pemetrexed therapy without compromising efficacy.

    Conclusions:

    • Homocysteine and methylmalonic acid are valuable biomarkers for predicting pemetrexed-induced toxicity.
    • Folic acid and vitamin B12 supplementation represent a viable strategy to mitigate severe adverse events associated with pemetrexed.
    • This approach enhances patient safety in pemetrexed-based chemotherapy regimens.